object
assess
util
panvir
dna
microarray
platform
virochip
detect
virus
associ
pediatr
respiratori
tract
infect
rti
virochip
compar
convent
direct
fluoresc
antibodi
dfa
polymeras
chain
reaction
pcr
base
test
detect
respiratori
virus
consecut
nasopharyng
aspir
sampl
children
virochip
superior
perform
dfa
show
increas
detect
respiratori
virus
includ
standard
dfa
panel
similar
virusspecif
pcr
sensit
specif
posit
predict
valu
neg
predict
valu
detect
respiratori
syncyti
viru
influenza
rhinovirusesenterovirus
virochip
also
detect
virus
routin
test
miss
dfa
pcr
well
doubl
infect
infect
critic
ill
patient
dfa
fail
detect
given
favor
sensit
specif
profil
expand
spectrum
detect
microarraybas
viral
test
hold
promis
clinic
diagnosi
pediatr
rti
j
pediatr
cute
respiratori
tract
infect
rti
common
ill
human
associ
signific
morbid
mortal
children
virus
respons
major
rti
bacteria
pathogen
thought
respons
fewer
case
howev
even
best
method
viral
detect
current
avail
specif
pathogen
identifi
rti
exist
viral
diagnost
method
limit
sensit
scope
viru
isol
cultur
take
day
week
mani
virus
remain
fastidi
uncultur
direct
fluoresc
antibodi
dfa
test
turnaround
time
hour
may
suffer
low
sensit
avail
limit
number
virus
polymeras
chain
reaction
pcr
test
rapid
highli
sensit
supplant
cultur
new
gold
standard
detect
respiratori
virus
research
set
howev
pcr
test
target
viru
time
make
assay
cumbersom
routin
clinic
practic
simultan
detect
virus
number
multiplex
pcr
assay
propos
recent
dna
microarray
test
emerg
promis
new
technolog
broadspectrum
viru
detect
previous
design
inhous
microarray
platform
detect
known
virus
well
novel
virus
relat
known
viral
famili
virochip
univers
california
san
francisco
ucsf
oligonucleotid
probe
repres
fulli
partial
sequenc
virus
genbank
fall
perform
virochip
respiratori
viru
detect
test
previous
use
viral
infect
tissu
cultur
cell
select
patient
cohort
date
virochip
compar
directli
standard
diagnost
test
virus
clinic
set
thu
present
studi
sought
compar
virochip
convent
clinic
dfaand
pcrbase
test
detect
respiratori
virus
associ
rti
children
studi
prospect
case
seri
consecut
sampl
sent
viral
dfa
test
pediatr
patient
seen
ucsf
decemb
june
patient
sampl
collect
accord
protocol
approv
ucsf
institut
review
board
consecut
nasopharyng
aspir
npa
sampl
sent
ucsf
clinic
laboratori
dfa
analyz
light
diagnost
respiratori
dfa
viral
screen
identif
kit
chemicon
intern
temecula
ca
kit
detect
common
respiratori
virus
respiratori
syncyti
viru
rsv
influenza
b
flua
flub
human
parainfluenza
viru
type
adenoviru
adv
remain
sampl
materi
transfer
steril
conic
tube
frozen
store
blind
virochip
analysi
frozen
npa
sampl
thaw
aliquot
use
extract
rna
use
rneasi
mini
kit
qiagen
inc
valencia
california
accord
manufactur
protocol
includ
oncolumn
dnase
digest
microarray
use
studi
ident
describ
previous
nation
center
biotechnolog
inform
geo
platform
rna
sampl
amplifi
label
use
round
ab
random
pcr
method
hybrid
virochip
report
previous
microarray
scan
axon
scanner
analyz
use
axon
genepix
softwar
axon
instrument
union
citi
california
microarray
data
submit
nation
center
biotechnolog
inform
geo
databas
access
number
virochip
data
analysi
carri
stage
first
microarray
analyz
epredict
algorithm
use
signific
valu
p
identifi
microarray
statist
signific
viral
hybrid
pattern
gener
optim
set
oligonucleotid
intens
weight
thirdgener
virochip
platform
took
remain
presum
neg
microarray
manual
fit
set
function
gener
equat
w
weight
valu
given
oligonucleotid
median
sumnorm
intens
oligonucleotid
across
neg
microarray
lower
boundari
median
median
sumnorm
intens
oligonucleotid
upper
boundari
condit
b
express
b
c
c
constant
standard
deviat
sumnorm
intens
oligonucleotid
across
neg
microarray
total
weight
set
c
p
fit
measur
evalu
use
epredict
profil
separ
statist
rhinoviru
rv
posit
rsvposit
fluaposit
microarray
optim
perform
achiev
weight
correspond
c
p
weight
use
gener
neg
null
distribut
base
set
neg
microarray
mention
final
microarray
viru
determin
made
epredict
microarray
consid
epredictposit
given
viru
correspond
energi
profil
attain
signific
valu
p
blind
reversetranscriptas
rt
pcr
assay
rsv
flua
rv
enteroviru
ev
perform
rna
extract
frozen
npa
sampl
viral
rickettsi
diseas
laboratori
california
depart
health
servic
detect
rsv
rtpcr
assay
rsv
target
fusion
f
gene
perform
use
access
rtpcr
system
describ
previous
detect
flua
primer
fluoresc
probe
target
highli
conserv
matrix
gene
flua
use
roch
lightcycl
realtim
pcr
system
roch
diagnost
indianapoli
indiana
describ
previous
detect
rvev
first
ran
inhous
rtpcr
multiplex
assay
randomli
prime
templat
cdna
use
primer
target
highli
conserv
untransl
region
rv
ev
posit
sampl
identifi
presenc
amplifi
pcr
band
expect
size
agaros
gel
electrophoresi
followup
realtim
pcr
assay
rvev
detect
discrep
sampl
virochip
inhous
multiplex
rtpcr
carri
use
roch
lightcycl
realtim
pcr
system
describ
previous
confirm
virochippositivepcrneg
sampl
done
pcr
use
altern
primer
base
highintens
microarray
oligonucleotid
direct
sequenc
sequenc
case
rsv
ident
fragment
matrix
gene
rsv
subgroup
b
strain
sequenc
case
rv
ident
fragment
region
rv
strain
anoth
virochippositivepcrneg
case
ev
confirm
repeat
run
realtim
pcr
assay
assay
result
npa
sampl
obtain
subject
identifi
retrospect
review
medic
record
perform
data
systemat
collect
use
standard
form
document
follow
inform
age
sex
date
locat
sampl
collect
clinic
present
presenc
immunocompromis
state
presenc
acut
respiratori
failur
dfa
result
locat
sampl
collect
classifi
outpati
clinic
emerg
depart
hospit
admiss
present
ill
defin
upper
rti
ie
cough
andor
congest
without
fever
clinician
diagnosi
lower
rti
ie
clinician
diagnosi
asthma
exacerb
bronchiol
croup
pneumonia
respiratori
ill
eg
febril
ill
seizur
dfa
collect
routin
basi
transplant
surgeri
immunocompromis
patient
defin
children
solid
organ
bone
marrow
transplant
congenit
acquir
immun
defici
includ
chemotherapi
human
immunodefici
viru
patient
respiratori
failur
defin
children
develop
acut
respiratori
decompens
necessit
mechan
ventil
result
respiratori
ill
patient
sampl
firsttim
sampl
defin
earliest
sampl
collect
singl
hospit
ill
analyz
total
npa
sampl
collect
children
presenc
virus
use
dfa
virochip
demograph
clinic
data
patient
given
tabl
patient
hospit
approxim
enrol
patient
n
acut
rti
remain
patient
n
dfa
sent
reason
often
nonrespiratori
febril
ill
n
eighteen
percent
patient
n
immunocompromis
n
develop
respiratori
failur
necessit
mechan
ventil
result
ill
subject
rsv
younger
mean
age
year
requir
hospit
wherea
subject
influenza
tend
older
mean
age
year
treat
mainli
outpati
case
human
metapneumoviru
hmpv
coronaviru
cov
adv
hospit
patient
major
viral
infect
immunocompromis
subject
due
picornavirus
figur
show
spectrum
frequenc
detect
differ
virus
method
patient
rti
tabl
ii
avail
wwwjpedscom
correspond
virus
typic
consid
respiratori
pathogen
see
text
virochip
detect
case
simultan
infect
virus
virochipposit
sampl
sampl
tabl
ii
avail
wwwjpedscom
contrast
dfa
detect
case
doubl
infect
virochip
also
detect
viral
pathogen
critic
ill
patient
develop
respiratori
failur
necessit
mechan
ventil
wherea
viru
detect
dfa
patient
two
doubl
infect
case
fluaadv
case
rsvrv
identifi
among
lifethreaten
case
assess
virochip
result
discord
dfa
overal
sensit
specif
carri
rtpcr
assay
rsv
flua
rvev
major
group
virus
detect
virochip
figur
detect
rsv
flua
overal
sensit
virochip
rel
pcr
significantli
better
dfa
p
analysi
correspond
specif
also
greater
overlap
posit
virochip
pcr
dfa
pcr
virus
virochippositivedfaneg
rsv
flua
sampl
confirm
true
posit
pcr
figur
venn
diagram
detect
rvev
first
use
inhous
rtpcr
multiplex
assay
base
method
report
previous
use
assay
npa
sampl
posit
virochip
pcr
npa
sampl
virochippositivepcrneg
npa
sampl
virochipnegativepcrposit
result
inconsist
rate
detect
use
clinic
valid
pcr
assay
virus
rsv
flua
analyz
discrep
sampl
blind
fashion
use
sensit
clinic
valid
realtim
pcr
assay
rvev
result
obtain
combin
assay
show
virochip
overal
high
sensit
specif
detect
rvev
figur
six
case
picornaviru
rsv
flua
detect
virochip
test
neg
correspond
pcr
assay
figur
hypothes
case
viral
strain
fail
detect
standard
pcr
primer
investig
possibl
recov
viral
sequenc
virochippositivepcrneg
case
rv
rsv
separ
confirm
case
ev
virochipposit
previous
pcrneg
repeat
realtim
pcr
assay
similar
attempt
confirm
remain
virochippositivepcrneg
case
limit
amount
sampl
avail
unsuccess
thu
least
virochippositivepcrneg
repres
pcr
falseneg
consequ
report
sensit
virochip
may
underestim
studi
pediatr
rti
use
dna
microarray
aim
detect
known
viral
speci
simultan
common
viral
pathogen
identifi
rsv
picornavirus
fluab
notabl
virus
detect
respiratori
tract
patient
nonrespiratori
ill
immunocompromis
patient
picornavirus
find
consist
observ
asymptomat
rv
infect
seen
healthi
individu
suggest
immunocompromis
host
may
suscept
colon
overt
respiratori
ill
picornavirus
frequenc
detect
picornavirus
consist
previous
publish
report
rv
ev
also
use
consecut
npa
sampl
comparison
virochip
dfa
demonstr
former
superior
sensit
respiratori
viru
detect
importantli
overal
increas
detect
rate
correspond
sampl
inconclus
dfa
result
due
low
cellular
content
unlik
dfa
nucleic
acid
detect
method
microarray
pcr
capabl
detect
free
viral
particl
addit
virusinfect
cell
anoth
signific
advantag
panvir
figur
comparison
perform
dfa
virochip
rel
pcr
dfa
virochip
compar
specif
pcr
use
conting
tabl
venn
diagram
analysi
detect
rsv
flua
b
addit
virochip
compar
specif
pcr
use
conting
tabl
detect
rv
ev
picornavirus
test
dfa
c
specif
pcr
assay
rvev
use
adequ
distinguish
rv
ev
result
report
total
number
rvevposit
case
microarray
dfa
abil
screen
known
virus
simultan
dfa
panel
current
clinic
use
test
rvev
hmpv
cov
studi
compos
detect
virus
patient
rti
patient
present
ill
sever
enough
requir
mechan
ventil
includ
case
critic
rv
infect
includ
immunocompromis
individu
rv
infect
thought
compris
spectrum
diseas
rang
asymptomat
infect
lifethreaten
childhood
pneumonia
find
case
critic
respiratori
tract
ill
associ
rv
infect
consist
grow
evid
link
rv
hospit
young
children
virochip
also
superior
dfa
detect
doubleviru
infect
two
case
doubl
infect
virus
could
detect
dfa
principl
character
singleviru
infect
dfa
previou
studi
suggest
doubleviru
infect
associ
greater
sever
rti
higher
effici
microarray
detect
critic
well
doubleviru
infect
import
advantag
method
time
detect
infect
may
allow
clinician
avoid
unnecessari
antibiot
invas
procedur
begin
appropri
antivir
treatment
avail
besid
highli
parallel
methodolog
use
thousand
oligonucleotid
probe
simultan
detect
dna
microarray
platform
like
virochip
expand
adapt
autom
oligonucleotid
design
allow
straightforward
addit
new
probe
better
detect
known
virus
well
expand
coverag
novel
evolv
viral
speci
dna
microarray
also
use
detect
nonvir
pathogen
includ
bacteria
fungi
interestingli
studi
virochip
detect
streptococcu
pyogen
bacteriophag
sampl
patient
aspir
pneumonia
also
posit
sputum
cultur
streptococcu
pyogen
result
suggest
possibl
strategi
use
phage
sequenc
indirect
mean
detect
bacteri
pathogen
despit
panvir
scope
virochip
detect
viru
rti
case
overal
although
compar
find
detect
method
result
like
underestim
true
number
posit
aris
sever
factor
first
sampl
may
miss
virochip
due
low
viru
titer
detect
limit
pcr
second
use
rna
rather
dna
sourc
materi
studi
may
given
rise
lowerthanexpect
rate
detect
dna
virus
adv
herpesvirus
parvovirus
virochip
may
detect
case
human
bocaviru
recent
describ
parvoviru
viru
share
low
sequenc
ident
parvoviru
sequenc
current
repres
virochip
final
patient
rti
studi
diagnos
pneumonia
hospitalassoci
mani
case
pneumonia
may
nonvir
origin
suggest
previou
epidemiolog
studi
pneumonia
hospit
children
use
custom
pcr
primer
confirm
least
microarraypositivepcrneg
case
rsv
rv
ev
true
posit
test
virus
detect
case
microarray
unexpect
virochip
use
multipl
probe
deriv
differ
site
viral
genom
higher
toler
sequenc
mismatch
primer
use
specif
pcr
result
improv
detect
diverg
virus
suspect
microarraypositivepcrneg
case
viru
infect
miss
clinic
pcr
like
due
mismatch
primer
target
sequenc
although
limit
specimen
avail
affect
abil
show
definit
although
prospect
comprehens
viral
detect
singl
microarray
assay
appeal
sever
challeng
must
address
use
technolog
becom
practic
clinic
diagnosi
first
set
technolog
entail
signific
initi
startup
cost
includ
cost
microarray
printer
viral
oligonucleotid
well
ongo
materi
labor
cost
second
turnaround
time
assay
current
hour
may
possibl
decreas
process
durat
use
ultrarapid
polymeras
amplif
control
agit
techniqu
hybrid
third
reproduc
consist
array
qualiti
concern
studi
none
microarray
assay
repeat
inher
probe
redund
built
method
make
assay
robust
purpos
viru
detect
exampl
oligonucleotid
probe
virochip
design
hybrid
rhinovirus
highintens
oligonucleotid
suffici
make
success
viru
identif
statist
method
interpret
microarray
data
exemplifi
epredict
complet
autom
allow
eas
use
freedom
oper
bia
smaller
microarray
aim
detect
target
viru
set
eg
respiratori
virus
would
reduc
cost
simplifi
issu
reproduc
qualiti
control
data
analysi
look
futur
envis
possibl
approach
use
viral
detect
microarray
clinic
practic
one
approach
would
use
platform
direct
diagnosi
respiratori
infect
report
altern
approach
could
deploy
viral
microarray
instrument
discoveri
rather
routin
detect
goal
identifi
diverg
unexpect
virus
elud
diagnosi
use
convent
method
new
candid
pathogen
identifi
specif
pcrbase
dfabas
assay
could
develop
detect
viru
high
degre
sensit
clinic
sampl
scenario
microarray
assay
would
complement
rather
replac
exist
diagnost
techniqu
pcr
